Article Sidebar
Views pdf: 33
HEPATOID ADENOCARCINOMA OF THE STOMACH: CASE REPORT AND LITERATURE REVIEW
Main Article Content
Abstract
Gastric cancer is a common cancer and known as a heterogeneous disease with many pathological and biological subgroups. Hepatoid adenocarcinoma of the stomach (HAS) is a rare subgroup, which accounts for 0.17-15% of all gastric cancers depending on the study, often metastasis to the lymph nodes, liver and having a poor prognosis. Due to many common characteristics, HAS can be misdiagnosed with Hepatocellular Carcinoma (HCC) in some cases. In this article, we report 2 cases diagnosed with HAS in Vietnam. Both cases had lesions in the liver area, increased AFP level and chronic hepatitis B, clinically it easily misdiagnosis with HCC. Treatments of these diseases are also completely different, as a result, the diagnosis plays an essential role and determines the entire course of the patient's future treatment. These two cases pose many challenges in making decisions in diagnosing the disease as well as the stage of the disease to provide the most appropriate treatment options for the patient.
Article Details
Keywords
Hepatoid adenocarcinoma of the stomach, Gastric cancer, Hepatocellular Carcinoma, AFP
References
2. Xia R, Zhou Y, Wang Y, Yuan J, Ma X. Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments. Front Oncol. 2021;11:950. doi:10.3389/ fonc.2021.633916
3. Hepatoid. Accessed September 5, 2021. https://www.pathologyoutlines.com/topic/stomachhepatoid.html
4. Zhao M, Sun L, Lai JZ, et al. Expression of RNA-binding protein LIN28 in classic gastric hepatoid carcinomas, gastric fetal type gastrointestinal adenocarcinomas, and hepatocellular carcinomas: An immunohisto-chemical study with comparison to SALL4, alpha-fetoprotein, glypican-3, and Hep Par1. Pathol Res Pract. 2018;214(10):1707-1712. doi:10.1016/ j.prp.2018.07.037
5. Bourreille J, Metayer P, Sauger F, Matray F, Fondimare A. [Existence of alpha feto protein during gastric-origin secondary cancer of the liver]. Presse Med. 1970;78(28):1277-1278.
6. Søreide JA.
Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives
. Ther Clin Risk Manag. 2019;15:1469-1477. doi:10.2147/TCRM.S204303
7. Isobe T, Hashimoto K, Kizaki J, et al. Characteristics and prognosis of gastric cancer in young patients. Oncol Rep. 2013;30(1):43-49. doi:10.3892/or.2013.2467
8. Inagawa S, Shimazaki J, Hori M, et al. Hepatoid adenocarcinoma of the stomach. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2001;4(1): 43-52. doi:10.1007/ s101200100016
9. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet Lond Engl. 2010;376(9742):687-697. doi:10.1016/S0140-6736(10)61121-X
10. Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016;140(12):1345-1363. doi:10.5858/ arpa.2016-0331-CP